Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Constipation and diarrhea each affected roughly 10-16% of participants
For patients without the aforementioned comorbidities with the primary goal of glycemic and weight management, GLP-1 and GIP/GLP-1 receptor agonists are recommended.(1) GLP-1 receptor agonists are not only efficacious for glucose lowering and achieving diabetes treatment goals, but have also demonstrated several added benefits in recent studies
Retatrutide, Eli Lilly's triple agonist, posted 24.2% body weight loss at the highest dose in Phase 2
This approval comes after thorough clinical trials that check for safety and effectiveness
US$ 27.31
US$ 29.14
US$ 21.88
US$ 22.07
US$ 29.84
